Table 2.
Vaccines for TGEV and PEDV.
| Virus | Region/country | Vaccines in development | Commercial vaccines |
|---|---|---|---|
| TGEV | North America | Recombinant proteins expressed in baculovirus, yeast, and plants; live attenuated vaccine; DNA vaccine | Live attenuated vaccines (mono, bi- and trivalent for TGEV, rota and E.coli) |
| Europe | Recombinant proteins expressed in baculovirus, yeast, and plants; live attenuated vaccine; DNA vaccine | Live attenuated vaccines (mono, bi- and trivalent for TGEV, rota and E.coli) | |
| Asia | Recombinant proteins expressed in baculovirus, yeast, and plants; live attenuated vaccine | Inactivated vaccines (mono, bi- and trivalent for TGEV, rota, PEDV and/or E.coli); live attenuated trivalent TGEV, PEDV and porcine rotavirus (China) | |
| PEDV | North America | Recombinant proteins expressed in yeast and baculovirus; DNA vaccine; infectious clone for live-attenuated vaccine | Inactivated vaccine; Recombinant alphavirus-based vaccine |
| Europe | DNA vaccine | Inactivated vaccines | |
| Asia | Recombinant vaccines expressed in baculovirus, yeast, plants, Lactobaccilus casei, Salmonella Typhimurium and others | Inactivated bi-valent TGEV and PEDV vaccine (China; strain CV777); Live attenuated tri-valent TGEV, PEDV and porcine rotavirus (China; PEDV strain CV777); Live attenuated vaccine (Japan; PEDV strain 83P-5; South Korea; PEDV strains SM98-1 and DR-13, Philippines, PEDV strain DR13); Inactivated vaccine (South Korea, PEDV strain SM98-1) |